Haleos Labs Limi

Which are the latest news on Haleos Labs Limi?

Why is Haleos Labs Limited falling/rising?

As of 05-Sep, Haleos Labs Limited's stock price is declining at 1,467.80, down 1.22% today and 3.85% over the last two days. The stock shows short-term weakness, trading below several moving averages, with a significant drop in investor participation.

As of 05-Sep, Haleos Labs Limited's stock price is falling, currently at 1,467.80, reflecting a decrease of 18.2 points or 1.22%. The stock has underperformed its sector by 0.9% today and has experienced a consecutive decline over the last two days, resulting in a total drop of 3.85% during this period. Additionally, the stock's performance over the past week shows a decline of 4.81%, while its one-month performance is down by 7.27%. <BR><BR>Investor participation appears to be decreasing, as evidenced by a significant drop in delivery volume, which fell by 84.74% compared to the five-day average. Although the stock is trading above its 100-day and 200-day moving averages, it is below its 5-day, 20-day, and 50-day moving averages, indicating a short-term weakness. Overall, these factors contribute to the current downward trend in Haleos Labs Limited's stock price.

Who are in the management team of Haleos Labs Limi?

The management team of Haleos Labs Limited includes T V V S N Murthy (Managing Director), P Sarath Kumar, Mannam Malakondaiah, Srinivas Samavedam, and P Venkata Subbarao (Independent Directors), Trupti Ranjan Mohanty (Company Secretary & Compliance Officer), Talluri Venkata Praveen (Executive Director), and Sudeepthi Gopin eedi (Whole-time Director). They oversee the company's operations and strategic direction.

The management team of Haleos Labs Limited includes the following individuals:<BR><BR>1. **T V V S N Murthy** - Managing Director<BR>2. **P Sarath Kumar** - Independent Director<BR>3. **Trupti Ranjan Mohanty** - Company Secretary & Compliance Officer<BR>4. **Talluri Venkata Praveen** - Executive Director<BR>5. **Sudeepthi Gopin eedi** - Whole-time Director<BR>6. **Mannam Malakondaiah** - Independent Director<BR>7. **Srinivas Samavedam** - Independent Director<BR>8. **P Venkata Subbarao** - Independent Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

What does Haleos Labs Limi do?

Haleos Labs Limited is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 73 Cr and a net profit of 3 Cr for June 2026. It was formerly known as SMS Lifesciences India Private Limited and has a market cap of INR 451 Cr.

Overview:<BR>Haleos Labs Limited operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated as "Potluri Real Estate Private Limited" in 2006, underwent several name changes, and became "SMS Lifesciences India Private Limited" in 2014 to focus on the pharma sector. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 73 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 3 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 451 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 28.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.10% <BR>Debt-Equity: 0.51 <BR>Return on Equity: 8.11% <BR>Price-to-Book: 2.18 <BR><BR>Contact Details:<BR>Address: Plot No 19-III Road No 71, Opp Bharatiya Vidya Bhavan PSc Hyderabad Telangana : 500096 <BR>Tel: 91-040-6628-8888 <BR>Email: info@smslife.in <BR>Website: http://www.smslife.in

Who are the peers of the Haleos Labs Limi?

Haleos Labs Limi's peers include Kilitch Drugs, Valiant Laborato, Albert David, Infinium Pharma, Medico Remedies, Ambalal Sarabhai, Jenburkt Pharma, Transchem, and Trident Lifeline. Haleos Labs Limi has a Below Average growth and capital structure, but the highest 1-year return among its peers at 29.48%.

Peers: The peers of Haleos Labs Limi are Kilitch Drugs, Valiant Laborato, Albert David, Infinium Pharma, Medico Remedies, Ambalal Sarabhai, Jenburkt Pharma, Transchem, and Trident Lifeline.<BR><BR>Quality Snapshot: Excellent management risk is observed at Medico Remedies and Jenburkt Pharma, while Average management risk is found at Haleos Labs Limi, Kilitch Drugs, and Transchem, and the rest. Below Average management risk is present at Valiant Laborato, Infinium Pharma, Ambalal Sarabhai, and the rest. In terms of growth, Good growth is seen at Kilitch Drugs and Medico Remedies, while Below Average growth is noted at Haleos Labs Limi, Valiant Laborato, Albert David, Infinium Pharma, Ambalal Sarabhai, and the rest. Excellent capital structure is held by Albert David and Infinium Pharma, while Good capital structure is noted at Kilitch Drugs and Medico Remedies, and Below Average capital structure is present at Haleos Labs Limi, Transchem, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Haleos Labs Limi at 29.48%, while the lowest is Transchem at 0.00%. Haleos Labs Limi's 1-year return is significantly higher than that of Transchem. Additionally, Medico Remedies and Transchem have negative six-month returns.

How big is Haleos Labs Limi?

As of 31st August, Haleos Labs Limited has a market capitalization of 451.00 Cr, with net sales of 324.23 Cr and a net profit of 15.81 Cr reported in the latest four quarters. Shareholder's funds are 196.56 Cr and total assets are valued at 389.99 Cr as of March 2025.

As of 31st August, Haleos Labs Limited has a market capitalization of 451.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Haleos Labs Limited reported net sales of 324.23 Cr and a net profit of 15.81 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with shareholder's funds amounting to 196.56 Cr and total assets valued at 389.99 Cr.

Are Haleos Labs Limited latest results good or bad?

Haleos Labs Limited's latest results are concerning, with a 36.30% decline in net profit and an 11.59% drop in net sales year-on-year, indicating significant operational challenges and negative market sentiment. Investors should exercise caution due to deteriorating fundamentals.

Haleos Labs Limited's latest results indicate a challenging financial situation. The company reported a consolidated net profit of ₹2.65 crores, which represents a significant decline of 36.30% year-on-year. Additionally, net sales fell to ₹72.94 crores, down 11.59% compared to the same quarter last year, marking the lowest quarterly performance in recent memory.<BR><BR>The operating margin also contracted, dropping to 12.49% from 14.19% in the previous year, highlighting ongoing profitability pressures. The profit after tax (PAT) margin decreased to 2.52%, down from 5.31% a year ago, reflecting substantial operational challenges.<BR><BR>Market reactions have been negative, with the stock trading below all key moving averages, indicating technical weakness. The company's proprietary advisory score is firmly in 'SELL' territory, reflecting deteriorating fundamentals and negative financial trends.<BR><BR>Overall, the results suggest that Haleos Labs is facing significant operational challenges, and the outlook appears concerning, warranting caution for investors.

Should I buy, sell or hold Haleos Labs Limited?

When is the next results date for Haleos Labs Limited?

Haleos Labs Limited will announce its results on 11 February 2026.

Haleos Labs Limited is scheduled to declare its results on 11 February 2026.

How has been the historical performance of Haleos Labs Limi?

Haleos Labs Limi showed improved financial performance in Mar'25, with net sales rising to 344.72 Cr and profit after tax increasing to 18.73 Cr, up from 6.33 Cr in the previous year. The company also reported enhanced operational efficiency, reflected in a significant rise in operating profit to 49.90 Cr.

Answer:<BR>The historical performance of Haleos Labs Limi shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Haleos Labs Limi's net sales increased from 305.96 Cr in Mar'24 to 344.72 Cr in Mar'25, following a dip in Mar'23. The total operating income also rose to 344.72 Cr in Mar'25 from 305.96 Cr in the previous year. The raw material costs slightly decreased to 149.91 Cr in Mar'25, while employee costs rose to 59.54 Cr, reflecting a growing workforce. Total expenditure, excluding depreciation, increased to 299.68 Cr in Mar'25 from 274.84 Cr in Mar'24. Operating profit (PBDIT) saw a significant rise to 49.90 Cr in Mar'25, up from 34.95 Cr in Mar'24, indicating improved operational efficiency. Profit before tax surged to 26.19 Cr in Mar'25, compared to 9.85 Cr in the prior year, leading to a profit after tax of 18.73 Cr, up from 6.33 Cr. The consolidated net profit also increased to 20.11 Cr in Mar'25 from 9.09 Cr in Mar'24. The company's total liabilities slightly decreased to 389.99 Cr in Mar'25 from 391.33 Cr in Mar'24, while total assets also saw a decline to 389.99 Cr. Cash flow from operating activities improved to 34.00 Cr in Mar'25, up from 24.00 Cr in Mar'24, indicating better cash generation from core operations. Overall, Haleos Labs Limi demonstrated a positive trend in profitability and operational performance in the latest fiscal year.

Who are the top shareholders of the SMS Lifesciences?

The top shareholder of SMS Lifesciences is Annapurna Talluri, holding 24.56%. Individual investors own 25.55%, while the highest public shareholder is Harita Projects Private with 1.57%.

The top shareholders of SMS Lifesciences include the promoters, with Annapurna Talluri holding the largest stake at 24.56%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors do not hold any shares in the company. Additionally, the highest public shareholder is Harita Projects Private, which holds 1.57%. Individual investors collectively own 25.55% of the shares.

Is SMS Lifesciences overvalued or undervalued?

As of May 30, 2025, SMS Lifesciences is considered undervalued with an attractive valuation grade, strong financial metrics, and a 67.7% return over the past year, significantly outperforming the Sensex.

As of 30 May 2025, the valuation grade for SMS Lifesciences has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued based on its strong financial metrics, including a PE ratio of 19.39, an EV to EBITDA ratio of 10.55, and a PEG ratio of 0.16, which suggests significant growth potential relative to its price. <BR><BR>In comparison to its peers, SMS Lifesciences stands out with a similar PE ratio to its closest competitor, while also demonstrating a more favorable PEG ratio, indicating that it may offer better growth prospects at its current valuation. Notably, the company's return over the past year has significantly outperformed the Sensex, with a remarkable 67.7% increase compared to the index's 7.57%. This performance reinforces the argument for its undervaluation in the market.

What is the technical trend for SMS Lifesciences?

As of June 5, 2025, SMS Lifesciences shows a mildly bearish trend due to bearish daily moving averages and a weak weekly RSI, despite some bullish signals from the MACD and KST on longer time frames.

As of 5 June 2025, the technical trend for SMS Lifesciences has changed from mildly bullish to mildly bearish. The weekly MACD remains bullish, but the monthly MACD is mildly bearish, indicating a divergence in time frames. The weekly RSI is bearish, while the monthly RSI shows no signal, suggesting weakness in momentum. Daily moving averages are bearish, reinforcing the current negative sentiment. The Bollinger Bands indicate a mildly bullish stance on both weekly and monthly charts, but this is overshadowed by the bearish signals from the daily moving averages and the weekly RSI. The KST is bullish on both weekly and monthly time frames, providing some support. However, the OBV shows a mildly bearish trend on the weekly, contrasting with a bullish monthly outlook. Overall, the current stance is mildly bearish, driven primarily by the bearish daily moving averages and the weekly RSI.

Has SMS Lifesciences declared dividend?

Yes, SMS Lifesciences India Ltd has declared a 15% dividend, amounting to ₹1.5 per share, with an ex-date of September 23, 2024. The company has shown strong price appreciation over various periods, with total returns reaching 353.05% over the last 5 years.

SMS Lifesciences India Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 1.5<BR>- Ex-date: 23 Sep 24<BR><BR>Dividend Yield: 0.12%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 11.55%, with a dividend return of 0%, resulting in a total return of 11.55%.<BR><BR>Over the past year, the price return reached 68.95%, while the dividend return was 0.19%, leading to a total return of 69.14%.<BR><BR>In the 2-year period, the price return was 146.28%, with a dividend return of 0.56%, culminating in a total return of 146.84%.<BR><BR>For the 3-year period, the price return stood at 83.85%, with a dividend return of 0.67%, resulting in a total return of 84.52%.<BR><BR>In the last 4 years, the price return was 105.78%, while the dividend return was 0.75%, leading to a total return of 106.53%.<BR><BR>Over the past 5 years, the price return was 351.06%, with a dividend return of 1.99%, resulting in a total return of 353.05%.<BR><BR>Overall, SMS Lifesciences has declared a dividend, contributing to a modest dividend yield, while the total returns over various periods indicate strong price appreciation, particularly over the longer term.